This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

SuperGen President & CEO Elected To BIO Board Of Directors

SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that its chairman, president and chief executive officer, James S.J. Manuso, Ph.D., has been elected to the Full Board of Directors of the Biotechnology Industry Organization (BIO) at its 2011 International Convention.

“I am honored to serve on the BIO Board of Directors,” said Dr. Manuso. “Collaborating with such an esteemed group of international life sciences leaders on health policy affecting oncology patients and those with other serious illnesses will hopefully enhance the effectiveness with which medical therapies are discovered, approved, and delivered.”

BIO’s Board of Directors is composed of members of the Governing Boards for each of BIO’s four sections: Health, Emerging Companies, Industrial & Environmental and Food & Agriculture. Dr. Manuso will serve on BIO’s Health Section Governing Board.

“I want to welcome Dr. Manuso to the Board, we are proud that he will be serving on BIO’s Full Board of Directors and on the Health Section Governing Board,” said Jim Greenwood, President and CEO of BIO. “His expertise and experience will be highly valuable to BIO’s critical policy development and advocacy activities.”

In addition, Dr. Manuso will serve on the BIO Board Standing Committee on International Affairs.

SuperGen has been a member of BIO since 2003. In addition to Dr. Manuso’s appointment to the Board, Nancy Worrell, SuperGen executive director, human resources, is the Co-Chair of the BIO Human Resources Conference 2011. The BIO Human Resources Conference 2011 has integrated events and offerings from the BIO International Convention.

About James S.J. Manuso, Ph.D.

Dr. Manuso has served as SuperGen chairman, president and chief executive officer since January 1, 2004, as chief executive officer-elect from September 2003 to December 2003 and as a director since February 2001. He is co-founder and immediate past president and chief executive officer of Galenica Pharmaceuticals, Inc.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs